Synthelis, a La Tronche, France-based company specializing in the production and characterization of therapeutic targets and antigens, secured €610k in funding.
The company intends to use the funds to accelerate the development of toll manufacturing services for membrane proteins for use by R&D departments in the pharmaceutical and biotechnology industries, as well as to consolidate and expand its functional and structural characterization services.
Founded in 2011 by Bruno Tillier, CEO, and Professor Jean-Luc Lenormand of the TIMC-TheREx laboratory at the Universite Joseph Fourier (UJF) in Grenoble, France, Synthelis develops and leverages an innovative patented technology for the acellular production of membrane proteins in the presence of liposomes. Applications include development of new therapeutic treatments and vaccines, screening for candidate drugs and in characterizing ligand/receptor interactions, diagnosis and structural biology, and in the development of antibodies.
In two years, the company has produced over 50 membrane proteins as part of more than 20 projects undertaken in conjunction with internationally-renowned pharmaceutical organizations.
Synthelis currently employs nine staff members.